Recent headlines proclaim a ‘potential’ or ‘functional’ cure for multiple myeloma, but the fight against the disease must ...

After a chaotic year that has seen the attrition of over half the FDA’s senior leadership, many of these individuals have ...

Under the terms of the deal, Gilead will put down $120 million in an upfront payment and will promise up to $1.52 billion in ...

CMS Administrator Mehmet Oz clarified that a deal has not yet been sealed with the manufacturer of semaglutide, Novo Nordisk, ...

The Commissioner’s National Priority Voucher awards companies that align with specific national priorities—such as boosting ...

Veradermics is the second hair regrowth specialist to fundraise this week, after Pelage Pharmaceuticals announced Wednesday ...

After the FDA revoked Sarepta Therapeutics’ platform designation in July, Krystal Biotech is “poised to be the first major ...

Nabla and Takeda first joined hands in 2022, to push “the boundaries of next-generation biologics discovery,” according to ...

EMD Serono will offer its fertility treatments on TrumpRx at a steep discount, and Roche’s direct-to-consumer offering will ...

Novo had around 250 employees working on cell therapies, all of whom will be laid off, though a spokesperson declined to ...

After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down ...

Moderna’s mRNA-4359, when used with Keytruda, achieves a 24% overall objective response rate in patients with melanoma, with ...